• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ProMIS Neurosciences Inc.

    10/16/24 4:51:37 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMN alert in real time by email
    SC 13G 1 tm2426305d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.    )*

     

     

     

    PROMIS NEUROSCIENCES INC.

    (Name of Issuer)

     

     

     

    Common Shares, no par value per share

    (Title of Class of Securities)

     

    74346M406

    (CUSIP Number)

     

    July 31, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

      1.    

    NAMES OF REPORTING PERSONS

     

    Shaf QIC LLC

      2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨       (b)  x

      

      3.  

    SEC USE ONLY

      

      4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    New Hampshire

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5.    

    SOLE VOTING POWER

     

    4,488,126*

      6.  

    SHARED VOTING POWER

     

    0

      7.  

    SOLE DISPOSITIVE POWER

     

    4,488,126*

      8.  

    SHARED DISPOSITIVE POWER

     

    0

      9.    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,488,126*

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ¨

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.99%*

    12.  

    TYPE OF REPORTING PERSON

     

    OO

     

    *    Consists (i) 2,394,063 Common Shares, no par value per share (the “Common Shares”) and (ii) 2,094,063 Common Shares issuable upon exercise of warrants that are currently exercisable. The reported warrants contain provisions preventing their exercise to the extent that such exercise would result in the holder (together with its affiliates) obtaining greater than 9.99% of the Issuer’s Common Shares (the “Beneficial Ownership Blocker”). However, the amounts reported in rows (5), (7) and (9) herein represent the number of Common Shares issuable upon exercise of the warrants in full, and do not give effect to the Beneficial Ownership Blocker. Therefore, the actual number of Common Shares beneficially owned by the Reporting Persons, after giving effect to the Beneficial Ownership Blocker, is less than the number of shares reported in rows (5), (7) and (9). The percent of class was calculated based upon 29,885,452 Common Shares of the Issuer outstanding as of August 15, 2024, as reported in the Issuer’s Definitive Proxy Statement filed with the Securities and Exchange Commission on September 9, 2024.

     

     

     

     

      1.    

    NAMES OF REPORTING PERSONS

     

    Jonathan Shafmaster

      2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ¨       (b)  x

      

      3.  

    SEC USE ONLY

      

      4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5.    

    SOLE VOTING POWER

     

    4,488,126*

      6.  

    SHARED VOTING POWER

     

    0

      7.  

    SOLE DISPOSITIVE POWER

     

    4,488,126*

      8.  

    SHARED DISPOSITIVE POWER

     

    0

      9.    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,488,126*

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ¨

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.99%*

    12.  

    TYPE OF REPORTING PERSON

     

    IN

     

    *    Consists of (i) 2,394,063 Common Shares and (ii) 2,094,063 issuable upon exercise of warrants that are currently exercisable. The reported warrants are subject to the Beneficial Ownership Blocker. However, the amounts reported in rows (5), (7) and (9) herein represent the number of Common Shares issuable upon exercise of the warrants in full, and do not give effect to the Beneficial Ownership Blocker. Therefore, the actual number of Common Shares beneficially owned by the Reporting Persons, after giving effect to the Beneficial Ownership Blocker, is less than the number of shares reported in rows (5), (7) and (9). The percent of class was calculated based upon 29,885,452 Common Shares of the Issuer outstanding as of August 15, 2024, as reported in the Issuer’s Definitive Proxy Statement filed with the Securities and Exchange Commission on September 9, 2024.

     

     

     

     

    Item 1.   Issuer
         
      (a) Name of Issuer:
         
        ProMIS Neurosciences Inc. (the “Issuer”)
         
      (b) Address of Issuer’s Principal Executive Offices:
         
       

    Suite 200, 1920 Yonge Street

        Toronto, Ontario, Canada M4S 3E2

     

    Item 2.   Filing Person
         
      (a) – (c) Name of Persons Filing; Address; Citizenship:
         
       

    (i)            Shaf QIC LLC, a New Hampshire limited liability company; and

    (ii)           Jonathan Shafmaster, a citizen of the United States of America. Mr. Shafmaster is the sole manager of Shaf QIC LLC.

     

    The address of the principal business office of the Reporting Persons is 158 Shattuck Way, Newington, NH 03801.

         
      (d) Title of Class of Securities:
         
        Common Shares, no par value per share (“Common Shares”).
         
      (e)

    CUSIP Number:

         
        74346M406
       

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
           
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
           
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
           
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
           
      (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:             
         
        If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:  

     

     

     

     

    Item 4. Ownership.
         
      (a) and (b)

    Amount beneficially owned:

         
        The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4.
         
      (c) Number of shares as to which such person has:

     

    Reporting Person     Sole Voting
    Power
          Shared
    Voting
    Power
          Sole
    Dispositive
    Power
          Shared
    Dispositive
    Power
          Percentage of
    Common Shares
    Outstanding
     
    Shaf QIC LLC     4,488,126 *     0       4,488,126 *     0       9.99 %*
    Jonathan Shafmaster     4,488,126 *     0       4,488,126 *     0       9.99 %*

     

    *Consists of (i) 2,394,063 Common Shares and (ii) 2,094,063 Common Shares issuable upon exercise of warrants that are currently exercisable. The reported warrants contain provisions preventing their exercise to the extent that such exercise would result in the holder (together with its affiliates) obtaining greater than 9.99% of the Issuer’s Common Shares (the “Beneficial Ownership Blocker”). However, the shares amounts reported herein represent the number of Common Shares issuable upon exercise of the warrants in full, and do not give effect to the Beneficial Ownership Blocker. Therefore, the actual number of Common Shares beneficially owned by the Reporting Persons, after giving effect to the Beneficial Ownership Blocker, is less than the number of shares reported in this Item 4(c). The percent of class was calculated based upon 29,885,452 Common Shares of the Issuer outstanding as of August 15, 2024, as reported in the Issuer’s Definitive Proxy Statement filed with the Securities and Exchange Commission on September 9, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.  
       
      Not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.  
       
      Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.  
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.  
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.  
       
      Not applicable.
       
    Item 10. Certification.  
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 16, 2024

     

    SHAF QIC LLC  
       
    /s/ Jonathan Shafmaster  

    Name: Jonathan Shafmaster

    Title: Manager

     

     
    /s/ Jonathan Shafmaster  

    JONATHAN SHAFMASTER

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit

     

    99.1Joint Filing Statement

     

     

    Get the next $PMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProMIS Neurosciences Announces First Quarter 2025 Financial Results

      First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease  Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2025. "We made significant

      5/12/25 7:30:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

      Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, March 31, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year end

      3/31/25 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

      CAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced plans to deliver virtual oral presentations at the 2025 Alzheimer's and Parkison's Disease (AD/PD) International Conference taking place in Vienna, Austria from April 1 - 4, 2025. The oral presentations are available on demand starting on Tuesday, April 1, 2025 at 7:00am C.E.T (2:00am E.T).

      3/24/25 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    SEC Filings

    See more
    • SEC Form 10-Q filed by ProMIS Neurosciences Inc.

      10-Q - ProMIS Neurosciences Inc. (0001374339) (Filer)

      5/12/25 7:39:20 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

      5/12/25 7:37:22 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ProMIS Neurosciences Inc.

      DEFA14A - ProMIS Neurosciences Inc. (0001374339) (Filer)

      4/29/25 5:15:09 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Cashman Neil bought $14,595 worth of shares (15,000 units at $0.97) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      2/12/25 5:21:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Shafmaster Madge K. bought $255,750 worth of shares (200,000 units at $1.28), increasing direct ownership by 2,400% to 208,333 units (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      9/24/24 6:56:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gordon Michael S bought $116,880 worth of shares (93,223 units at $1.25) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      9/18/24 4:15:05 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Cashman Neil bought $14,595 worth of shares (15,000 units at $0.97) (SEC Form 4)

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      2/12/25 5:21:35 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Milbury Max A.

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      11/20/24 7:04:11 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Development Officer Kaplan Johanne

      4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

      11/20/24 7:03:06 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Leadership Updates

    Live Leadership Updates

    See more
    • ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-

      5/14/24 4:01:00 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve

      4/1/24 4:15:00 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProMIS Neurosciences, Inc. Announces Leadership Transition

      CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a strategic leadership change. The Company's Board of Directors appointed Neil Warma, a highly-qualified biotechnology industry executive and ProMIS Board member, as interim Chief Executive Officer to succeed Gail Farfel, Ph.D., who has stepped down to pursue other opportunities. Mr. Warma's appoint

      1/3/24 7:00:00 AM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

      SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/14/24 4:56:13 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ProMIS Neurosciences Inc.

      SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/14/24 3:36:04 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

      SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

      11/6/24 4:15:57 PM ET
      $PMN
      Biotechnology: Pharmaceutical Preparations
      Health Care